Nykode Therapeutics AS
OSL: NYKD.OL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Oslo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Thyring Engsig
- Employees
- 135
- Headquarters
- Oslo, Norway
- IPO year
- 2020
- Market cap
- NOK 1.0B
- Website
- https://nykode.com
Loading NYKD…
Loading profile data…Frequently asked questions about NYKD
What does Nykode Therapeutics AS (NYKD.OL) do?
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, b...
Where does NYKD.OL trade?
Nykode Therapeutics AS (NYKD.OL) trades on the Oslo Stock Exchange.
What sector is NYKD.OL in?
Nykode Therapeutics AS (NYKD.OL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nykode Therapeutics AS?
Michael Thyring Engsig is the chief executive officer of Nykode Therapeutics AS (NYKD.OL).
Where is Nykode Therapeutics AS headquartered?
Nykode Therapeutics AS is headquartered in Norway.
Does NYKD.OL pay a dividend?
Yes — Nykode Therapeutics AS (NYKD.OL) paid a trailing twelve-month dividend of NOK 1.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did NYKD.OL go public?
Nykode Therapeutics AS (NYKD.OL) completed its initial public offering in 2020.